When is it safe to start semaglutide or tirzepatide after stopping breastfeeding
PMID: 41093057 Adv Sci (Weinh) The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice
References [1] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W, Hsu, Y, Pang, J.S., 2014 [2] National Library of Medicine, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., Apostolakos, J., July 2025 [3] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W., Hsu, Y., Pang, JS., November 2014
El riesgo absoluto de pancreatitis con semaglutida es muy bajo (aproximadamente 0,1 0,2 %) y en los meta-anlisis no se ha observado un incremento significativo respecto a los placebos
Tirzepatide demonstrates HbA1c reductions ranging from 1.9-2.6% across its dosing spectrum